TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone

Journal of Drugs in Dermatology

Volumn 9, Issue 11, 2010, Pages 1368-1372

  Martiniuk, Frank ^a   Damian, Diona L ^a   Thompson, John F ^a   Scolyer, Richard A ^a   Tchou Wong, Kam Meng ^b   Levis, William R ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DIPHENCYPRONE; IMIQUIMOD; RNA; TRANSCRIPTION FACTOR FOXP3; CYCLOPROPANE DERIVATIVE; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; HAPTEN; INTERLEUKIN 17; KRUPPEL LIKE FACTOR; LEUKOCYTE ANTIGEN; ZBTB16 PROTEIN, HUMAN;

ACCESSORY CELL; ANTIGEN EXPRESSION; ARTICLE; DENDRITIC CELL; GENE EXPRESSION; GENE LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOTHERAPY; LYMPHOCYTE; MELANOMA; METASTATIC MALIGNANT MELANOMA; PIGMENTATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCALP; SCALP DISEASE; SKIN DISEASE; TH1 CELL; TH17 CELL; AGED; CASE REPORT; GENETICS; IMMUNOLOGY; MALE; METABOLISM; METASTASIS; OINTMENT; PATHOLOGY; SKIN TUMOR; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; ANTIGENS, CD; CYCLOPROPANES; HAPTENS; HUMANS; INTERLEUKIN-17; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MELANOMA; OINTMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SCALP; SKIN NEOPLASMS; TH17 CELLS;

EID: 79952113738     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Asarch A, Barak O, Loo DS, et al. Th17 cells: A new therapeutic target in inflammatory dermatoses. J Dermatolog Treat. 2008;19:318-326.
2. Zaba LC, Fuentes-Duculan J, Eungdamrong NJ, et al. Poriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells. J Invest Dermatol. 2009;129:79-88.
3. Martiniuk F, Lee D, Gaspari A, et al. Expression of human CD70 and the transcription factor RORgT in human contact dermatitis. J Drugs Dermatol. 2008;7:956-960.
4. He D, Lizhi Wu, Hee Kyung Kim, et al. IL-17 and IFN-{gamma} mediate the elicitation of contact hypersensitivity responses by different mechanisms and both are required for optimal responses. J Immunol. 2009;183:1463-1470.
5. Larsen JM, Bonefeld CM, Poulsen SS, et al. IL-23 and T(H)17-mediated inflammation in human allergic contact dermatitis. J Allergy Clin Immunol. 2009;123:486-492.
6. Zhao Y, Balato A, Fishelevich R, et al. Th17/Tc17 infiltration and associated cytokine gene expression in elicitation phase of allergic contact dermatitis. Br J Dermatol. 2009;161:1301-1306.
7. Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362-373.
8. Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone. J Am Acad Dermatol. 2007;56:869-891.
9. Damian DL, Shannon KF, Saw RP, et al. Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Austr J Dermatol. 2009;50:266-271.
10. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121-1133. (Pubitemid 44380299)
11. Motegi SI, Okazawa H, Murata Y, et al. Essential roles of SHPS-1 in induction of contact hypersensitivity of skin. Immunol Lett. 2008;121:52-60.
12. Gober MD, Fishelevich R, Zhao Y, et al. Human natural killer T cells infiltrate into the skin at elicitation sites of allergic contact dermatitis. J Invest Dermatol. 2008;128:1460-1469. (Pubitemid 351693190)
13. Gober MD, Gaspari AA. Allergic contact dermatitis. Curr Dir Autoimmun. 2008;10:1-26.
14. Holzer AM, Kaplan LL, Levis WR. Haptens as drugs: Contact allergens are powerful topical immunomodulators. J Drugs Dermatol. 2006;5:410-416.
15. Holzer AM, Levis WR. Antiviral immunotherapy: Emerging approaches with relevance to cutaneous disease. Exp Rev Dermatol. 2007;2:619-627. (Pubitemid 350065063)
16. Huang J, Kerstann KW, Ahmadzadeh M, et al. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: Importance for the therapeutic effectiveness of cell transfer immunotherapy. J Immunol. 2006;176:7726-7735. (Pubitemid 43849073)
17. Radhakrishnan S, Cabrera R, Schenk EL, et al. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo. J Immunol. 2008;181:3137-3147.
18. Keller AM, Groothuis TA, Veraar EA, et al. Costimulatory ligand CD70 is delivered to the immunological synapse by shared intracellular trafficking with MHC class II molecules. Proc Natl Acad Sci. 2007;104:5989-5994. (Pubitemid 47175646)
19. Vossen MT, Matmati M, Hertoghs KM, et al. CD27 defines phenotypically and functionally different human NK cell subsets. Immunol. 2008;180:3739-3745.
20. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117:3498-506. (Pubitemid 350097005)
21. Ambrosino E, Berzofsky JA, Terabe M. Regulation of tumor immunity: The role of NKT cells. Expert Opin Biol Ther. 2008;8:725-734. (Pubitemid 351860202)
22. Watanabe H, Gaide O, Pétrilli V, et al. Activation of the IL-1beta-processing inflammasome is involved in contact hypersensitivity. J Invest Dermatol. 2007;127:1956-1963. (Pubitemid 47075373)
23. Watanabe H, Gehrke S, Contassot E, et al. Danger signaling through the inflammasome acts as a master switch between tolerance and sensitization. J Immunol. 2008;180:5826-5832.
24. Martin SF, Dudda JC, Bachtanian E, et al. Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity. J Exp Med. 2008;205:2151-2162.
25. Martin-Orozco N, Muranski P, Chung Y, et al. Helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009;31:787-798.
26. Weber J. Overcoming immunologic tolerance to melanoma: Targeting CTLA-4 with ipilimumab (MDX-010). Oncologist. 2008;13:16-25.
27. Wang W, Edington HD, Rao UNM, et al. Effects of highdose IFNA2b on regional lymph node metastases of human melanoma:modulation of STAT5, FOXP3, and IL-17. Clin Cancer Res. 2008;14:8314-8320.
28. Matsumura S, Wang B, Kawashima N, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181:3099-3107.
29. Motsinger A, Haas DW, Stanic AK, et al. CD1d-restricted human natural killer T cells are highly susceptible to human immunodeficiency virus 1 infection. J Exp Med. 2002;195:869-879. (Pubitemid 34286758)
30. Gaida MM, Günther F, Wagner C, et al. Expression of the CXCR6 on polymorphonuclear neutrophils in pancreatic carcinoma and in acute, localized bacterial infections. Clin Exp Immunol 2008;154:216-223.
31. Tuckermann JP, Kleiman A, Moriggl R, et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J Clin Invest. 2007;117:1381-1390. (Pubitemid 46718426)
32. Green DS, Dalgleish AG, Belonwu N, et al. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br J Dermatol. 2008;159:606-614.
33. Sun BK, Tsao H. Small RNAs in development and disease. J Am Acad Dermatol. 2008;59:725-737.
34. Felicetti F, Errico MC, Segnalini P, et al. MicroRNA-221 and -222 pathway controls melanoma progression. Expert Rev Anticancer Ther. 2008;8:1759-1765.
35. Muljo SA, Ansel KM, Kanellopoulou C, et al. Aberrant T cell differentiation in the absence of Dicer. J Exp Med. 2005;202:261-269. (Pubitemid 41043822)
36. Wu H, Neilson JR, Kumar P, et al. miRNA profiling of naïve, effector and memory CD8 T cells. PLoS ONE. 2007;2:e1020.